De novo purine metabolism is a metabolic vulnerability of cancers with low p16 expression
Cancer Res Commun. 2024 Apr 16. doi: 10.1158/2767-9764.CRC-23-0450. Online ahead of print.ABSTRACTp16 is a tumor suppressor encoded by the CDKN2A gene whose expression is lost in ~50% of all human cancers. In its canonical role, p16 inhibits the G1-S phase cell cycle progression through suppression of cyclin dependent kinases. Interestingly, p16 also has roles in metabolic reprogramming, and we previously published that loss of p16 promotes nucleotide synthesis via the pentose phosphate pathway. However, the broader impact of p16/CDKN2A loss on other nucleotide metabolic pathways and potential therapeutic targets remains u...
Source: Cancer Control - April 16, 2024 Category: Cancer & Oncology Authors: Naveen Kumar Tangudu Raquel Buj Hui Wang Jiefei Wang Aidan R Cole Apoorva Uboveja Richard Fang Amandine Amalric Baixue Yang Adam Chatoff Claudia V Crispim Peter Sajjakulnukit Maureen A Lyons Kristine Cooper Nadine Hempel Costas A Lyssiotis Uma R Chandran Source Type: research
GSE236046 Polysome profiling experiment in control and VARS-depleted RES M395 melanoma cultures
Contributors : Najla El-Hachem ; Arnaud Lavergne ; Pierre CloseSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensIn this project, we identify novel translational targets of VARS in primary melanoma cultures by the use of polysome profiling. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 16, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Other Homo sapiens Source Type: research
GSE236642 Ribosome sequencing experiment in control and VARS-depleted RES M395 melanoma cultures
Contributors : Najla El-Hachem ; Coralie Capron ; Pierre CloseSeries Type : Expression profiling by high throughput sequencing ; OtherOrganism : Homo sapiensIn this project, we identify novel translational targets of VARS in primary melanoma cultures by the use of ribosome sequencing. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 16, 2024 Category: Genetics & Stem Cells Tags: Expression profiling by high throughput sequencing Other Homo sapiens Source Type: research
GSE236645 Comparison of tRNA abundance profiling in primary M395 melanoma cultures SENS or RES to 1 µM Vemurafenib
Contributors : Najla El-Hachem ; Pierre CloseSeries Type : Non-coding RNA profiling by high throughput sequencingOrganism : Homo sapiensIn this project, we aim at studying differential tRNA expression or dynamics in sensitive and resistance melanoma primary cultures. (Source: GEO: Gene Expression Omnibus)
Source: GEO: Gene Expression Omnibus - April 16, 2024 Category: Genetics & Stem Cells Tags: Non-coding RNA profiling by high throughput sequencing Homo sapiens Source Type: research
Mucosal Melanoma of Palate: A Case Report with Review of Literature
AbstractThe World Health Organisation defines mucosal malignant melanoma as a malignant tumour of melanocytes or of melanocyte progenitors. Due to the lack of symptoms and unknown etiology, mucosal malignant melanoma may go undiagnosed. The surgeon can find it challenging to come up with a definitive treatment strategy because of its rarity and rapid spread. In this case study, a 57-year-old female patient with hyperpigmented gingiva and palate diagnosed pathologically and immunohistochemically as malignant melanoma underwent surgical excision and a modified radical neck dissection. (Source: Journal of Maxillofacial and Oral Surgery)
Source: Journal of Maxillofacial and Oral Surgery - April 16, 2024 Category: ENT & OMF Source Type: research
Could the mitotic count improve personalized prognosis in melanoma patients?
In conclusion, these findings revealed the need to include the mitotic rate in the histological diagnosis because it correlates with the prognosis as an independent factor. The mitotic rate can be used to develop a personalized medicine approach in the treatment and follow-up monitoring of melanoma patients. (Source: PLoS One)
Source: PLoS One - April 16, 2024 Category: Biomedical Science Authors: Alessandra Buja Source Type: research
Cancers, Vol. 16, Pages 1520: Identification and In Vivo Validation of Unique Anti-Oncogenic Mechanisms Involving Protein Kinase Signaling and Autophagy Mediated by the Investigational Agent PV-10
Narendran
PV-10 is a 10% formulation of rose bengal sodium that has potent immunotherapeutic and anti-cancer activity against various tumors, including metastatic melanoma and refractory neuroblastoma. Currently, PV-10 is undergoing clinical testing for refractory metastatic neuroendocrine cancer and melanomas. However, preclinical investigation of PV-10 activity and its mechanisms against phenotypically and molecularly diverse adult solid tumors had not been conducted. In a panel of human cell lines derived from breast, colorectal, head and neck, and testicular cancers, we demonstrated that PV-10 induces cytotoxicity ...
Source: Cancers - April 16, 2024 Category: Cancer & Oncology Authors: Son Tran Patrick Sipila Satbir Thakur Chunfen Zhang Aru Narendran Tags: Article Source Type: research
Lifileucel: First Approval
This article summarizes the milestones in the development of lifileucel leading to this first approval for the treatment of patients with unresectable or metastatic melanoma who have progressed on or after prior anti-PD-1/L1 therapy and targeted therapy. (Source: Molecular Diagnosis and Therapy)
Source: Molecular Diagnosis and Therapy - April 16, 2024 Category: Molecular Biology Source Type: research
MNK1/2 inhibition limits oncogenicity and metastasis of KIT-mutant melanoma
(Source: Journal of Clinical Investigation)
Source: Journal of Clinical Investigation - April 15, 2024 Category: Biomedical Science Authors: Yao Zhan, Jun Guo, William Yang, Christophe Goncalves, Tomasz Rzymski, Agnieszka Dreas, Eliza Żyłkiewicz, Maciej Mikulski, Krzysztof Brzózka, Aniela Golas, Yan Kong, Meng Ma, Fan Huang, Bonnie Huor, Qianyu Guo, Sabrina Daniela da Silva, Jose Torres, Yu Source Type: research
The Crown Jewel: Checkpoint Inhibition in Unresectable Cutaneous Squamous Cell Carcinoma
This is a complex case1 requiring multidisciplinary assessment. Given his non-melanoma skin cancer history, consideration should be given to whether the biopsy is representative of the entire lesion. We would not recommend upfront surgery for this locally advanced cutaneous squamous cell carcinoma with likely transdural spread and parenchymal brain and posterior sagittal sinus involvement. The survival for these cases is poor,2 and resection of the posterior sagittal sinus carries a high risk of venous infarction. (Source: International Journal of Radiation Oncology * Biology * Physics)
Source: International Journal of Radiation Oncology * Biology * Physics - April 15, 2024 Category: Radiology Authors: Lachlan McDowell, Catherine Barnett Tags: Gray Zone Expert Opinion Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: Journal of Rheumatology)
Source: Journal of Rheumatology - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
Upadacitinib in Rheumatoid Arthritis and Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs: Efficacy and Safety Through 5 Years (SELECT-NEXT)
CONCLUSION: The 5-year benefit-risk profile for upadacitinib in RA remains favorable.PMID:38621793 | DOI:10.3899/jrheum.2023-1062 (Source: J Rheumatol)
Source: J Rheumatol - April 15, 2024 Category: Rheumatology Authors: Gerd R Burmester Filip Van den Bosch John Tesser Anna Shmagel Yanxi Liu Nasser Khan Heidi S Camp Alan Kivitz Source Type: research
